FDA Issues Highest Risk Warning for Vegetable Recall
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A recall of a range of vegetable products due to potential contamination with Listeria monocytogenes has been issued the highest risk classification by the U.S. Food and Drug Administration (FDA).
And Go Concepts LLC, doing business as Salad and Go, a Texas-based company, announced a voluntary recall for the products on May 27.
The FDA subsequently issued a Class 1 risk classification for the recall on July 11.
Newsweek contacted And Go Concepts LLC for comment by email outside of regular working hours.
Salad and Go announced a voluntary recall for a range of vegetable products due to potential listeria contamination on May 27.
Salad and Go announced a voluntary recall for a range of vegetable products due to potential listeria contamination on May 27.
Edwin Remsberg/VWPics/AP
Why It Matters
A Class I risk classification represents "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death," according to the FDA.
Listeria infection, or listeriosis, may lead to a range of symptoms in infected individuals. For those experiencing less severe infections, symptoms may include fever, muscle aches, nausea, vomiting and diarrhea, which often last between one and three days, the FDA said.
For more severe and potentially life-threatening infections, symptoms may include headaches, stiff neck, confusion, loss of balance and convulsions.
Severe infections are particularly dangerous for young children, frail or elderly people, and those with weakened immune systems. It can also lead to miscarriages and stillbirths in pregnant women.
What To Know
The products affected by the recall include the following:
Red cabbage, shredded - 1 case - codes: 2514111 / 2514111B
Onion, red diced - 8 cases (80 bags) - codes: 2514111 / 2514111B / 2514211 / 2514211B / 2514311
Cucumber, sliced - 8 cases (80 bags) - codes: 2514111 / 2514311
Pepper, red bell chopped - 31 cases (220 bags) - codes: 2514111 / 2514111B / 2514311
Carrot, shredded - 16 cases (195 bags) - codes: 2514111 / 2514311
Tomato, grape - 141 cases (565 bags) - codes: 2514111 / 2514111B / 2514211
Potato, cooked breakfast - codes: 2514111 / 2514111B / 2514311
Brussels sprouts, roasted - 71 cases - codes: 2514111 / 2514111B / 2514311
The products were distributed in Arizona and Nevada.
What People Are Saying
Mary O'Riordan, a professor of microbiology and immunology at the University of Michigan Medical School, told Newsweek previously: "Listeria has an unusual capacity to grow at refrigerated temperatures. Although the bacterium can contaminate many types of food, cheeses or deli meats that are kept in cold storage for long periods in stores or at home are a place where listeria can keep growing.
"Early symptoms of listeria infection look similar to other common foodborne infections, including fever, diarrhea and vomiting, so it's often not diagnosed right away. Unfortunately, sometimes listeria can spread into the brain and cause more serious illness, like meningitis. In those cases, if people experience headache, stiff neck or confusion, they should seek urgent medical attention."
Haley F. Oliver, a professor of food science at Purdue University, told Newsweek previously: "Listeria monocytogenes is a common microorganism that can be found in the natural environment, for example in soil. There are many factors that determine if someone gets listeriosis—a listeria infection. In most instances, an immunocompromised person—so young, old, pregnant or otherwise immunocompromised—must eat contaminated food. The number of bacteria resulting in infection and the amount of time before illness varies considerably. Symptoms vary among people but can include fever, flu-like symptoms, headache, stiff neck, confusion and loss of balance."
The FDA says on its website: "Pregnant women and their unborn or newborn baby, adults over the age of 65, and those with weakened immune systems, are all considered to be high-risk groups that are susceptible to the serious and adverse effects of listeriosis."
What Happens Next
The recall is listed as completed, according to the FDA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Nalu Medical Achieves National Payer Milestone with Aetna Coverage for PNS Therapy
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc., a leader in miniaturized neuromodulation therapies, is pleased to announce that Aetna Inc. has issued an updated medical policy designating the Nalu Neurostimulation System as medically necessary for the treatment of chronic pain of peripheral nerve origin. This change, effective July 31, 2025, marks a critical milestone in Nalu's mission to expand access to safe, innovative, drug-free alternatives for chronic pain relief. This policy shift moves Nalu from its prior classification of 'Investigational/Experimental' to 'Medically Necessary' for eligible patients—opening access to more than 22 million additional covered lives across the U.S. 'Aetna's recognition of Nalu as a medically necessary therapy is a powerful validation of our technology, clinical evidence, and commitment to patient outcomes,' said Tom West, Chief Executive Officer of Nalu Medical. 'We've built a robust body of clinical data demonstrating that Nalu PNS provides safe, effective, and durable relief for patients living with chronic, intractable pain, as well as healthcare economic data that demonstrates use of Nalu PNS results in significant cost savings. We're proud to see a leading payer like Aetna acknowledge that value, and we look forward to engaging with other health plans to expand access to this life-changing therapy.' Chronic peripheral nerve pain is often debilitating and unresponsive to conventional therapies, including long-term medication and surgery. The Nalu Neurostimulation System offers a minimally invasive, drug-free alternative that delivers precise electrical stimulation to targeted peripheral nerves, providing long-lasting relief while reducing the risks of opioid dependency and avoiding systemic side effects. About the Nalu Neurostimulation System The Nalu System consists of a fully featured, battery-free, miniaturized implantable pulse generator (IPG) 1 that is powered wirelessly by an externally worn Therapy Disc and controlled through a smartphone-based remote control app. Despite its small size, the Nalu micro-IPG™ delivers treatment capabilities similar to larger IPGs as well as advantages associated with advanced waveforms, extensive programming options, exceptional upgradability, and an expected service life of 18 years. The Nalu Neurostimulation System has been repeatedly recognized for its revolutionary technology, including being named as one of the world's top 100 new products by R&D Magazine in 2021 and ranking number 19 in the 2023 Deloitte Technology Fast 500. It is FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. To learn more, visit About Nalu Medical, Inc. Nalu is a Carlsbad, California-based medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain. The Nalu Neurostimulation System was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians. [1] Data on file, Nalu Medical, Inc. 2025.
Newsweek
21 minutes ago
- Newsweek
FDA Issues Risk Warning for Potato Chips Recall
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of potato chips due to the possible presence of an undeclared allergen has been issued the second-highest risk warning by the U.S. Food and Drug Administration (FDA). Saratoga Potato Chips LLC, based in Indiana, issued a voluntary recall for more than 2,000 bags of chips due to the undeclared presence of milk on July 7. The FDA subsequently issued a Class II risk classification on July 15. Newsweek contacted Saratoga Potato Chips LLC for comment by email. Stock image. Saratoga Potato Chips LLC issued a voluntary recall for more than 2,000 bags of crisps due to the undeclared presence of milk on July 7. Stock image. Saratoga Potato Chips LLC issued a voluntary recall for more than 2,000 bags of crisps due to the undeclared presence of milk on July 7. Robert Michael/picture-alliance/dpa/AP Images Why It Matters A Class II risk classification refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA. The recall was initiated due to the undeclared presence of milk, one of the nine major food allergens as defined in law. The others are eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans and sesame. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems. What To Know The product impacted by the recall is the following: - J. Higgs Potato Chip Mix - 2275 bags - UPC code: 0-51933-37327-3 - best if used by date: October 5, 2025 The product was distributed to retail locations in Maryland, Kentucky, Florida and Indiana. What People Are Saying The FDA says on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, told Newsweek previously: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." What Happens Next The recall is listed as ongoing, according to the FDA. People with sensitivities or allergies to milk should not consume the affected product.
Associated Press
38 minutes ago
- Associated Press
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
By Meg Flippin Benzinga DETROIT, MICHIGAN - July 16, 2025 ( NEWMEDIAWIRE ) - Lance Alstodt, CEO of BioRestorative Therapies (NASDAQ: BRTX), was recently a guest on Benzinga's All-Access. BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to achieve those goals. The company's flagship product candidate, BRTX-100, just completed a phase 2 clinical trial for chronic lumbar disc disease (cLDD), which Alstodt was on hand to discuss with Benzinga. 'Data from the first 36 patients was highly encouraging,' Alstodt told Benzinga in the interview. 'At 52 weeks over 74% of participants demonstrated greater than 50% improvement in function and over 72% reported a greater than 50% reduction in pain, both substantially exceeding the FDA's clinically meaningful threshold of 30%,' Alstodt said the phase 2 outcome set the stage for a pivotal trial or even accelerated path to approval. BRTX-100 is an autologous stem cell product for chronic lower back pain. It uses a patient's stem cells, which are harvested, cultured and then injected directly into the affected disc to start the repair process. During the interview, Alstodt told Benzinga that he thinks what makes BRTX-100 different is that instead of masking the pain, like opioids and injectables, the BioRestorative product candidate is targeting the root cause. The goal of the phase 2 trials is to enroll a total of 99 patients, which the CEO said is tracking well. An announcement on that front is expected soon. But that's not all Alstodt revealed in this wide-ranging interview. From BioRestorative's expansion plans to what's next for the company, the executive had a lot to share in this must-watch All Access interview. Watch the full interview here: Featured image fromShutterstock. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originallypublished on further disclosureshere.
